Trust Company of Vermont’s Antares Pharma, Inc. ATRS Stock Holding History

Trust Company of Vermont’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,000	Closed	-$4K	–	790
2021 Q4	$4K	Buy	+1,000	New	+$3.5K	﹤0.01%	746
2021 Q3	–	Sell	-1,000	Closed	-$4K	–	763
2021 Q2	$4K	Hold	1,000	–	–	﹤0.01%	718
2021 Q1	$4K	Hold	1,000	–	–	﹤0.01%	694
2020 Q4	$4K	Hold	1,000	–	–	﹤0.01%	699
2020 Q3	$3K	Hold	1,000	–	–	﹤0.01%	695
2020 Q2	$3K	Hold	1,000	–	–	﹤0.01%	720
2020 Q1	$2K	Hold	1,000	–	–	﹤0.01%	830
2019 Q4	$5K	Hold	1,000	–	–	﹤0.01%	799
2019 Q3	$3K	Hold	1,000	–	–	﹤0.01%	913
2019 Q2	$3K	Buy	+1,000	New	+$2.89K	﹤0.01%	929

Other funds holding ATRS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Trust Company of Vermont's ATRS Position: Q1 2022 in Review

Trust Company of Vermont sold out of Antares Pharma, Inc. (ATRS) in Q1 2022, closing a stake of 1,000 shares — an estimated $4K sold.

Trust Company of Vermont first reported a position in ATRS in Q2 2019 and held it in 10 quarters. The position peaked at $5K in Q4 2019. 177 funds tracked by Wall St. Rank hold ATRS as of Q1 2022.

Trust Company of Vermont reported no remaining Antares Pharma, Inc. position as of Q1 2022 after selling out during the quarter.
Trust Company of Vermont sold 1,000 Antares Pharma, Inc. shares in Q1 2022, an estimated $4K.
Trust Company of Vermont first reported a position in Antares Pharma, Inc. in Q2 2019 and held it in 10 quarters.
Trust Company of Vermont's Antares Pharma, Inc. position peaked at $5K in Q4 2019.
177 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2022.

Based on Trust Company of Vermont's 13F filing for Q1 2022, filed 5 Apr 2022.